Abstracts tagged "neutrophils and vasculitis"

Abstract Number: 2719 • 2017 ACR/ARHP Annual Meeting
Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?
Tadeja Kuret¹, Katja Lakota^1,2, Polona Žigon¹, Manca Ogrič¹, Boris Lestan¹, Snezna Sodin Semrl^1,2, Saša Čučnik^1,3, Matija Tomšič^1,4 and Alojzija Hočevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, ³Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, ⁴University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Background/Purpose: Immunoglobulin A vasculitis (IgAV, formerly Henoch–Schönlein purpura) is a small vessel, immune complex vasculitis characterized by dominant IgA deposits in the vascular wall. Clinical…
Abstract Number: 860 • 2015 ACR/ARHP Annual Meeting
Neutrophil/Lymphocyte Ratio: Could It be a Prognostic Indicator for Renal Outcome in Patients with Granulomatosis with Polyangiitis?
Berna Goker¹, Seminur Haznedaroglu¹, Hamit Kucuk¹, Ozkan Varan¹, Berivan Bitik¹, Abdurrahman Tufan¹, Ridvan Mercan¹ and Yasemin Erten², ¹Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²Internal Medicine-Nephrology, Gazi University Medical School, Ankara, Turkey
Background/Purpose: Neutrophil/lymphocyte ratio (NLR) has recently been extensively studied as a prognostic indicator in various malignancies, as well as an indicator of severity in cardiovascular…
Abstract Number: 856 • 2012 ACR/ARHP Annual Meeting
Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculitisthrough the Suppression of Neutrophil Migration and Activation
Chie Miyabe¹, Yoshishige Miyabe¹, Noriko Miura², Kei Takahashi³, Yuya Terashima⁴, Etsuko Toda⁴, Fumiko Honda⁵, Tomohiro Morio⁵, Naohito Ohno², Jun-ichi Suzuki⁶, Mitsuaki Isobe⁷, Kouji Matsushima⁴, Ryoji Tsuboi⁸, Nobuyuki Miyasaka¹ and Toshihiro Nanki⁹, ¹Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ²Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan, ³Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan, ⁴Department of Molecular Preventive Medicine, The University of Tokyo, Tokyo, Japan, ⁵Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan, ⁷Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁸Department of Dermatology, Tokyo Medical University, Tokyo, Japan, ⁹Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Vasculitis is characterized by leukocyte infiltration in the vessel walls with destructive damage to mural structures. Retinoids are compounds that bind to retinoic acid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].